instruction:
Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.
question:
The coronavirus, which emerged in China late last year, has decimated global markets as it quickly moves around the world. It appeared poised for a spike in the United States, in part because of more testing to confirm cases. Florida late Sunday declared a public health emergency as it confirmed its first two cases. Trump administration officials worked Sunday to soothe nerves and calm fears that a global recession was looming, arguing that the public and media were over-reacting and saying that stocks would bounce back because the American economy was fundamentally strong. The total number of confirmed cases in the United States is more than 75 with two reported deaths, both in Washington state. Globally there have been more than 87,000 cases and nearly 3,000 deaths in 60 countries, according to the World Health Organization. In the United States, a cluster of cases is centered on a nursing home near Seattle. The Seattle and King County public health department confirmed late Sunday that a man in his 70s who was a resident of the LifeCare long-term care facility in Kirkland and had coronavirus had died the day before. On Saturday, the department had reported the first death of a coronavirus patient in the United States, a man in his 50s who was living in Kirkland - the same city where the nursing home is located. Six of the 10 confirmed coronavirus cases in Washington state have been residents or workers at LifeCare. State officials said an additional 27 residents of the nursing home and 25 staff members were reporting symptoms of the virus, which can be similar to that of the common flu. New York Governor Andrew Cuomo confirmed on Twitter his state’s first coronavirus case, a woman in her 30s who caught the virus during a recent trip to Iran and was now in home quarantine. Cuomo did not say where the woman lived, but the New York Times reported she was in the Manhattan borough of New York City, citing state officials. “The patient has respiratory symptoms, but is not in serious condition and has been in a controlled situation since arriving in New York,” Cuomo said. Stock markets plunged last week, with an index of global stocks setting its largest weekly fall since the 2008 financial crisis, and more than $5 trillion wiped off the value of stocks worldwide. A key energy conference in Houston that brings together oil ministers and energy firms was canceled on Sunday with the organizers of CERAWeek noting that border health checks were becoming more restrictive and companies had begun barring non-essential travel to protect workers. A world economy conference with Pope Francis due to take place in Italy later this month was also canceled. Trump said on Sunday that travelers to the United States from countries at high risk of coronavirus would be screened before boarding and on arrival, without specifying which countries. Delta Air Lines Inc said on Sunday it was suspending until May flights to Milan in northern Italy, where most of that country’s coronavirus cases have been reported. Flights will continue to Rome. American Airlines Group Inc announced a similar move late on Saturday. The United States has 75,000 test kits for coronavirus and will expand that number “radically” in coming weeks, U.S. Health and Human Services Secretary Alex Azar told ABC’s “This Week” on Sunday. Vice President Mike Pence, appointed last week to run the White House’s coronavirus response, said the government had contracted 3M Co to produce an extra 35 million respiratory masks a month. He urged Americans not to buy the masks, which he said were only needed by healthcare workers. Honeywell International Inc is the other major U.S. mask producer. He also told Fox News that clinical trials of a coronavirus vaccine would start in six weeks but that a vaccine would likely not be available this season. Democrats, who will challenge Trump for the presidency in the Nov. 3 election, have criticized his administration for downplaying the crisis and not preparing for the disease to spread in the United States. Pence said Americans should brace for more cases but that the “vast majority” of those who contracted the disease would recover. “Other than in areas where there are individuals that have been infected with the coronavirus, people need to understand that for the average American, the risk does remain low. We’re ready,” Pence told NBC’s “Meet the Press.”
answer:
Washington state confirms second U.S. coronavirus death; New York reports first case.


question:
This release doesn’t discuss costs in its comparison of influenza shots versus nasal sprays, although both modes of immunization have been around for a long while and the costs for both are easily known. While flu immunizations are often free through public health clinics and such, some people receive their immunizations from their family physicians and carry a specific cost. Knowing the difference in costs between the two types is useful information both for people and public health officials. The release reports similar rates of vaccine uptake for intranasal vaccine and standard flu shots. But it does not quantify benefits for the main outcome of the study, that is, rates of influenza in communities vaccinated with nasal vs injected vaccine over the course of the study. These rates were statistically no different: 5.2% for the standard vs 5.3% for the nasal vaccine. This release makes no mention of possible harms that my follow the use of either the influenza vaccine injections or nasal spray, even though there are well-known restrictions on whom should and should not receive the nasal spray, and potential negative reactions to the injections among some people. The release points out that the study was the “first blinded randomized controlled trial” done in children within largely closed communities and it found similar efficacy in using the two modes of immunization. However, we do wish the release had addressed limitations, as well as some of the complexity of making these results generalizable to a larger population, as we saw with NPR’s take on the news. While media attention is routinely heightened leading up to and during flu season, this release does not appear to reach the level of disease mongering. The release does identify the chief funder of the study, the Canadian Institutes for Health Research, although it offers no information on possible conflicts of interest among any of the researchers. The abstract of the study does state that two of the researchers do have links to pharmaceutical firms, but not in relation this study. Since the study looked a two forms of influenza vaccine administration, it obviously addresses the question of comparing alternatives. Both forms of immunization — shots and nasal spray — have been around for some time, their availability is widely known, earning the release a Satisfactory in this category. The release makes clear that the novelty of this study is its ability to examine both indirect effects of vaccination on the community as well as direct effects for persons receiving the vaccine. The release does not use any unjustifiable language.
answer:
Flu nasal spray provides similar protection against influenza as flu shot: Study


question:
A GlaxoSmithKline logo is seen outside one of its buildings in west London, February 6, 2008. REUTERS/Toby Melville The GlaxoSmithKline Plc vaccine Rotarix fights infection with the rotavirus, which causes about 55,000 hospitalizations in U.S. children each year and kills more than 600,000 children worldwide, mostly in developing countries. Rotarix already is approved in more than 100 other countries throughout the world. The vaccine competes with Merck & Co Inc’s rotavirus vaccine called RotaTeq. Without vaccination, nearly every child in the United States likely would be infected at least once with rotavirus by age five, the Food and Drug Administration said. In studies of more than 24,000 infants, Rotarix prevented severe and mild cases of rotavirus-caused diarrhea and vomiting during the first two years of life. “This vaccine provides another option to combat and reduce a potentially severe illness that affects so many children,” Dr. Jesse Goodman, director of the FDA’s Center for Biologics Evaluation and Research, said in a statement announcing the Rotarix approval. The most common reactions reported during clinical trials were fussiness, irritability, cough, runny nose, fever, loss of appetite and vomiting, the FDA said. An earlier oral rotavirus vaccine sold by Wyeth was pulled from the market in 1999 after it was linked to a rare, life-threatening type of bowel obstruction known as intussusception. In a Glaxo study of more than 63,000 infants, there was no increase in the problem compared with a placebo. Higher rates of convulsion and pneumonia-related deaths were seen in Rotarix patients in that study but not in other Glaxo trials. “Although the FDA has concluded that the available data do not establish that these events are related to the vaccine, the agency has requested the manufacturer to conduct post-marketing safety studies involving more than 40,000 infants to provide additional safety information,” the FDA said. Glaxo said Rotarix “will offer protection against the most commonly circulating rotavirus types in the U.S. and allow infants to complete the vaccination series by four months of age.”   Rotarix, which is a liquid, is given in two doses to infants from six to 24 weeks of age, the FDA said. Merck’s RotaTeq vaccine is administered in three doses from ages six weeks to 32 weeks. Sales of Rotarix were $182 million in 2007 and are expected to rise with approval in the large U.S. market. The vaccine will be commercially available in the United States in the second half of the year, Glaxo said. Also on Thursday, researchers reported that Rotarix provided protection for up to two years in a study of infants from 10 Latin American countries. The Glaxo-funded trial of more than 15,000 infants found severe diarrhea from rotavirus in 0.4 percent of children given the vaccine, compared with 2.3 percent in the placebo group. Results were published in the Lancet medical journal. The arrival of a new generation of oral vaccines against the disease has been welcomed by health-care workers, but some experts caution against assuming the vaccines will work equally well in all countries. In a commentary in the Lancet, Australian pediatric experts Keith Grimwood and Carl Kirkwood noted Rotarix was more effective in European trials than in middle-income Latin American countries. The World Health Organization “is awaiting efficacy data from low-income countries of Africa and Asia, where much greater strain diversity exists and where 413,000 deaths occur every year compared with 15,000 in Latin America and 200 in Europe,” Grimwood and Kirkwood wrote.
answer:

Glaxo wins FDA clearance for rotavirus vaccine.